(Q38176387)

30 August 2017

title

Current management options for liposarcoma and challenges for the future (English)

1 reference

30 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24397249%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Attila Kollár

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24397249%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

1 reference

8 January 2014

1 reference

Expert Review of Anticancer Therapy

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24397249%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24397249%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24397249%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

297-306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24397249%20AND%20SRC:MED&resulttype=core&format=json

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Atypical and malignant lipomatous lesions of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Pleomorphic liposarcoma: clinical observations and molecular variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Predicting survival for well-differentiated liposarcoma: the importance of tumor location.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Differential sensitivity of liposarcoma subtypes to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Myxoid liposarcoma. Experience with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase II study of docetaxel in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

New activities for the anti-tumor agent trabectedin: taking two birds with one stone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

A phase II trial with rosiglitazone in liposarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase I study of nelfinavir in liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Genomic investigation of dedifferentiated liposarcoma suggests a role for therapeutic targeting of the tumor epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173

Lymphocyte Composition and Distribution in Inflammatory, Well-differentiated Retroperitoneal Liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.869173